Page 6 - Immune Sciences News Today

Wolfe Research started coverage on shares of Alpine Immune Sciences (NASDAQ:ALPN – Free Report) in a report released on Thursday, MarketBeat.com reports. The brokerage issued an outperform rating and a $44.00 target price on the biotechnology company’s stock. Other analysts have also recently issued reports about the stock. Royal Bank of Canada lifted their target […]

Research analysts at Wolfe Research initiated coverage on shares of Alpine Immune Sciences (NASDAQ:ALPN – Get Free Report) in a report released on Thursday, Briefing.com reports. The firm set an “outperform” rating and a $44.00 price target on the biotechnology company’s stock. Wolfe Research’s price target points to a potential upside of 51.05% from the […]

Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Free Report)’s share price traded down 4% during trading on Tuesday . The stock traded as low as $26.34 and last traded at $26.34. 347,216 shares changed hands during trading, a decline of 65% from the average session volume of 991,954 shares. The stock had previously closed at […]

SEATTLE--(BUSINESS WIRE)--Feb 1, 2024--

Alpine Immune Sciences, Inc. , a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company...

U.S. stocks traded higher, with the Dow Jones gaining around 50 points on Thursday. Shares of Alaska Air Group, Inc. (NYSE: ALK) rose during Thursday’s session following upbeat earnings.

Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance.

Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Free Report) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 3,980,000 shares, an increase of 32.7% from the December 15th total of 3,000,000 shares. Based on an average daily volume of 788,500 shares, the short-interest […]

Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Free Report) were up 3.8% during trading on Wednesday . The stock traded as high as $20.31 and last traded at $20.25. Approximately 255,066 shares were traded during mid-day trading, a decline of 40% from the average daily volume of 425,013 shares. The stock had previously […]

Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Free Report) has earned a consensus rating of “Buy” from the six research firms that are presently covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have issued a report on the stock in […]